4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bS)-3a-(2-(dimethylamino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(3-(2-morpholinoethoxy)prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid | 1621532-54-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bS)-3a-(2-(dimethylamino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(3-(2-morpholinoethoxy)prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid
• 英文别名: 4-[(1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bS)-3a-[2-(dimethylamino)ethylcarbamoyl]-5a,5b,8,8,11a-pentamethyl-1-[3-(2-morpholin-4-ylethoxy)prop-1-en-2-yl]-1,2,3,4,5,6,7,7a,11,11b,12,13,13a,13b-tetradecahydrocyclopenta[a]chrysen-9-yl]benzoic acid
• CAS: 1621532-54-4
• 化学式: C₄₇H₇₁N₃O₅
• 分子量: 758.098
• InChiKey: YEKANLSRGBKSAT-YEUPLEGISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  55
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  91.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bS)-3a-(2-(dimethylamino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(3-(2-morpholinoethoxy)prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate 、 sodium hydroxide 以 1,4-二氧六环 为溶剂， 反应 15.0h， 以to give the product (14 mg, 0.018 mmol, 37% yield) as a white solid的产率得到4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bS)-3a-(2-(dimethylamino)ethylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(3-(2-morpholinoethoxy)prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid
  参考文献：
  名称：

  C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY

  摘要：

  本文提供了具有药物和生物影响特性的化合物、它们的制药组合物和使用方法。特别是，提供了具有独特抗病毒活性的C-19修饰三萜类化合物，作为HIV成熟抑制剂，如公式I和II所示的化合物：这些化合物对治疗HIV和艾滋病有用。

  公开号：

  US20140221361A1

文献信息

• [EN] C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY<br/>[FR] TRITERPÉNOÏDES MODIFIÉS EN C-19 AYANT UNE ACTIVITÉ INHIBANT LA MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014123889A1

  公开（公告）日：2014-08-14

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-19 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas (I) and (II), wherein R1 is as defined herein and does not represent either an isopropyl or isopropenyl group: (Formula (I)) and (Formula (II)). These compounds are useful for the treatment of HIV and AIDS.